Literature DB >> 10211986

Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues.

T Ohnishi1, S Hiraga, S Izumoto, H Matsumura, Y Kanemura, N Arita, T Hayakawa.   

Abstract

In order to clarify the role of fibronectin in glioma invasion in vivo, we analyzed the relationship between fibronectin-stimulated cell migration and adhesion in 14 primary glioma cells and the expression of fibronectin and the fibronectin receptor in the corresponding tumor tissues. The tumors comprised nine glioblastomas (GB) and five anaplastic gliomas (AG) consisting of two astrocytomas, two oligoastrocytomas and one ependymoma. All glioma cells tested in the primary cell culture were found to migrate to fibronectin in a dose-dependent manner. The extent of cell migration to fibronectin was not significantly different for the GB and AG groups. On the other hand, cell adhesion to fibronectin in the AG was much stronger than that in the GB group. Immunohistochemistry demonstrated that fibronectin positively stained in the extracellular matrix (ECM) in eight cases and that the fibronectin receptor was positive in tumor cell membranes in 10 cases. In addition, cellular fibronectin isoforms containing ED-A and ED-B sequences were found to be immunolocalized in the tumor cells and the ECM of GB. These isoforms were also specifically expressed in tumor vessels within tumor tissues, but not in those within normal brain tissues. Cell migration tended to be expressed more strongly by glioma cells derived from tumor tissues in which fibronectin was positively immunolocalized in the ECM than from tissues with negative fibronectin in the ECM. Four glioma cells derived from GB whose tumor cells did not positively stain for fibronectin receptors migrated much less extensively to fibronectin than other glioma cells whose tissues showed positive staining for the fibronectin receptor. Of these four GB, two had loss of heterozygosity in the locus of fibronectin receptor beta1 gene. These results suggest that fibronectin deposited in the extracellular matrix of tumors, which can be derived from both plasma and the tumor cell itself, strongly promotes the migration of glioma cells, and that expression of the fibronectin receptor may play a critical role in the biological behavior of the tumor cells, particularly in fibronectin-stimulated cell migration in vivo.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10211986     DOI: 10.1023/a:1006532812408

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  43 in total

1.  Changes in integrin receptors on oncogenically transformed cells.

Authors:  L C Plantefaber; R O Hynes
Journal:  Cell       Date:  1989-01-27       Impact factor: 41.582

Review 2.  Integrins: a family of cell surface receptors.

Authors:  R O Hynes
Journal:  Cell       Date:  1987-02-27       Impact factor: 41.582

3.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

4.  Adhesion activity in fibronectin's alternatively spliced domain EDa (EIIIA) and its neighboring type III repeats: oncogene-dependent regulation.

Authors:  P Xia; L A Culp
Journal:  Exp Cell Res       Date:  1994-07       Impact factor: 3.905

5.  Distribution of a major connective tissue protein, fibronectin, in normal and neoplastic human nervous tissue.

Authors:  A Paetau; K Mellström; A Vaheri; M Haltia
Journal:  Acta Neuropathol       Date:  1980       Impact factor: 17.088

6.  Determinants of human astrocytoma migration.

Authors:  A Giese; M D Rief; M A Loo; M E Berens
Journal:  Cancer Res       Date:  1994-07-15       Impact factor: 12.701

7.  Temporal effects of dexamethasone on blood-to-brain and blood-to-tumor transport of 14C-alpha-aminoisobutyric acid in rat C6 glioma.

Authors:  W R Shapiro; E M Hiesiger; G A Cooney; G A Basler; L E Lipschutz; J B Posner
Journal:  J Neurooncol       Date:  1990-06       Impact factor: 4.130

8.  Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors.

Authors:  T Nakagawa; T Kubota; M Kabuto; K Sato; H Kawano; T Hayakawa; Y Okada
Journal:  J Neurosurg       Date:  1994-07       Impact factor: 5.115

9.  Assignment of the gene encoding the beta-subunit of the human fibronectin receptor (beta-FNR) to chromosome 10p11.2.

Authors:  P J Goodfellow; H A Nevanlinna; P Gorman; D Sheer; G Lam; P N Goodfellow
Journal:  Ann Hum Genet       Date:  1989-01       Impact factor: 1.670

10.  Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.

Authors:  E A Wayner; A Garcia-Pardo; M J Humphries; J A McDonald; W G Carter
Journal:  J Cell Biol       Date:  1989-09       Impact factor: 10.539

View more
  37 in total

1.  A unique model system for tumor progression in GBM comprising two developed human neuro-epithelial cell lines with differential transforming potential and coexpressing neuronal and glial markers.

Authors:  Anjali Shiras; Arti Bhosale; Varsha Shepal; Ravi Shukla; V S Baburao; K Prabhakara; Padma Shastry
Journal:  Neoplasia       Date:  2003 Nov-Dec       Impact factor: 5.715

2.  Inhibiting Fibronectin Attenuates Fibrosis and Improves Cardiac Function in a Model of Heart Failure.

Authors:  Iñigo Valiente-Alandi; Sarah J Potter; Ane M Salvador; Allison E Schafer; Tobias Schips; Francisco Carrillo-Salinas; Aaron M Gibson; Michelle L Nieman; Charles Perkins; Michelle A Sargent; Jiuzhou Huo; John N Lorenz; Tony DeFalco; Jeffery D Molkentin; Pilar Alcaide; Burns C Blaxall
Journal:  Circulation       Date:  2018-09-18       Impact factor: 29.690

Review 3.  Biological mechanisms of glioma invasion and potential therapeutic targets.

Authors:  B B Tysnes; R Mahesparan
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

4.  Cartilage differentiation in ependymoma: histogenetic considerations on a new case.

Authors:  Antonella Coli; Mariangela Novello; Luca Massimi; Massimo Caldarelli; Valentina Ranucci; Libero Lauriola
Journal:  Childs Nerv Syst       Date:  2014-01-22       Impact factor: 1.475

5.  Deletion of the SPARC acidic domain or EGF-like module reduces SPARC-induced migration and signaling through p38 MAPK/HSP27 in glioma.

Authors:  Heather M McClung; William A Golembieski; Chad R Schultz; Michelle Jankowski; Lonni R Schultz; Sandra A Rempel
Journal:  Carcinogenesis       Date:  2011-11-23       Impact factor: 4.944

6.  SERPINA5 inhibits tumor cell migration by modulating the fibronectin-integrin β1 signaling pathway in hepatocellular carcinoma.

Authors:  Ying Jing; Deshui Jia; Chun-Ming Wong; Irene Oi-Lin Ng; Zhenfeng Zhang; Li Liu; Qifeng Wang; Fangyu Zhao; Jinjun Li; Ming Yao; Xingzhong Wu; Xianghuo He
Journal:  Mol Oncol       Date:  2013-12-18       Impact factor: 6.603

7.  Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinoma.

Authors:  Shanna A Arnold; Lee B Rivera; Andrew F Miller; Juliet G Carbon; Sean P Dineen; Yang Xie; Diego H Castrillon; E Helene Sage; Pauli Puolakkainen; Amy D Bradshaw; Rolf A Brekken
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

8.  IGFBP2 is overexpressed by pediatric malignant astrocytomas and induces the repair enzyme DNA-PK.

Authors:  Oren J Becher; Katia M Peterson; Soumen Khatua; Maria R Santi; Tobey J MacDonald
Journal:  J Child Neurol       Date:  2008-10       Impact factor: 1.987

9.  Treatment of glioblastoma using multicomponent silica nanoparticles.

Authors:  O Turan; P A Bielecki; V Perera; M Lorkowski; G Covarrubias; K Tong; A Yun; Georgia Loutrianakis; S Raghunathan; Y Park; T Moon; S Cooley; D Dixit; M A Griswold; K B Ghaghada; P M Peiris; J N Rich; E Karathanasis
Journal:  Adv Ther (Weinh)       Date:  2019-09-04

Review 10.  Engineering strategies to mimic the glioblastoma microenvironment.

Authors:  Andrew Rape; Badriprasad Ananthanarayanan; Sanjay Kumar
Journal:  Adv Drug Deliv Rev       Date:  2014-08-29       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.